Hormonal
Dapagliflozin, an SGLT2 inhibitor, significantly reduces cardiovascular risk and mortality in type 2 diabetes patients by correcting major risk factors like obesity and hypertension, unlike older therapies which may increase risk.
If you have Type 2 Diabetes and are at high risk for heart problems, ask your doctor about Dapagliflozin. It is a daily pill that not only helps control blood sugar but has been proven to significantly reduce the risk of heart attacks, strokes, and heart failure hospitalizations compared to older treatments. It also helps with weight loss and blood pressure.
Показано преимущество дапаглифлозина — перорального противодиабетического препарата нового поколения, обладающего надежным и безопасным противодиабетическим действием и способностью к коррекции основных факторов сердечно-сосудистого риска (ожирение, артериальная гипертензия).
Why this rating
Based on large-scale RCTs (EMPA-REG, CANVAS, DECLARE) cited in the review.
Source
Cardiovascular risk in type 2 diabetes patients
О. Д. Остроумова et al. · CARDIOVASCULAR THERAPY AND PREVENTION · 2018
DOI 10.15829/1728-8800-2018-4-81-94
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →